Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 223 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Deep-Vein Thrombosis Clear all
Completed Phase 3 Interventional Results available

Cancer Venous Thromboembolism (VTE)

NCT02073682
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
Interventions
Edoxaban, Dalteparin, Low molecular weight heparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 1, 2026, 9:09 PM EDT
Recruiting No phase listed Observational

Non-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression.

NCT06519435
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Mayo Dopplex ABIlity, Intermittent Pneumatic Compression (IPC)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 1, 2026, 9:09 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease

NCT04583878
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Blood draw (Visit 1), Blood draw (Visits 2 and 3)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 21 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • St. Petersburg, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Early Phase 1 Interventional

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

NCT03516656
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions
Standard heparin dose, Real time heparin dose adjustment
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Not applicable Interventional Results available

Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT

NCT03195777
View directory record Official record
Conditions
Deep Venous Thrombosis, Post-thrombotic Syndrome
Interventions
PET/CT
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 1, 2026, 9:09 PM EDT
Terminated Phase 3 Interventional

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

NCT05171049
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Abelacimab, Apixaban
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Aurora, Colorado • West Haven, Connecticut • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Not applicable Interventional Results available

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735
View directory record Official record
Conditions
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions
ActiveCare CECT device, Enoxaparin
Device · Drug
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Sep 1, 2026, 9:09 PM EDT
Recruiting No phase listed Observational

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

NCT07102160
View directory record Official record
Conditions
Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature, Venous Embolism, Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts
Interventions
Aspiration thrombectomy system
Device
Lead sponsor
Argon Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Tampa, Florida • Edgewood, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 1, 2026, 9:09 PM EDT
Terminated Phase 2 Interventional Results available

Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

NCT03003390
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 1, 2026, 9:09 PM EDT
Not listed Not applicable Interventional

SToP: Venous Thromboembolism Screening in the Trauma Population

NCT02978950
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Trauma, Multiple
Interventions
Duplex ultrasound surveillance, No ultrasound surveillance
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Results available

Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)

NCT01014403
View directory record Official record
Conditions
Venous Thromboembolism, Traumatic Brain Injury
Interventions
enoxaparin, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Dallas, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Sep 1, 2026, 9:09 PM EDT
Terminated Phase 2 Interventional Results available

Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer

NCT00633061
View directory record Official record
Conditions
Childhood Cancer, Central Venous Catheters, Deep Vein Thrombosis, Catheter-related Infection, Catheter-related Occlusion
Interventions
Enoxaparin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 1, 2026, 9:09 PM EDT
Terminated No phase listed Observational

Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis

NCT02078154
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Not listed
Lead sponsor
Diagnostica Stago
Industry
Eligibility
Up to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

NCT02303431
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Edoxaban low dose, Edoxaban high dose
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
0 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Non-Interruptive Alerts for Improving Use of Clinical Decision Rules

NCT04702308
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Minor Head Injury, Chest Pain, Neck Trauma
Interventions
Clinical Decision Rule Alerts
Other
Lead sponsor
University of Utah
Other
Eligibility
16 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Not applicable Interventional

The Protrieve PROTECTOR Study

NCT06495996
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis
Interventions
Percutaneous mechanical thrombectomy (PMT)
Device
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
15
States / cities
Newport Beach, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Phase 4 Interventional

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

NCT01828697
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin, Intermediate dose enoxaparin, Low dose dalteparin, Intermediate dose dalteparin, Fixed low dose tinzaparin, Intermediate dose tinzaparin
Drug
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Phase 3 Interventional Results available

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

NCT00056550
View directory record Official record
Conditions
Antithrombin Deficiency, Congenital
Interventions
Recombinant Human Antithrombin (rhAT)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Marietta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Not applicable Interventional Results available

Education Bundle to Decrease Patient Refusal of VTE Prophylaxis

NCT02402881
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Patient-centered education bundle
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
19,652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 1, 2026, 9:09 PM EDT
Completed No phase listed Observational

Multi-Center Human Alert Trial to Prevent DVT and PE

NCT00409136
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Human Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2009 · Synced Sep 1, 2026, 9:09 PM EDT
Not yet recruiting Phase 4 Interventional

Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease

NCT07713875
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
Interventions
Apixaban
Drug
Lead sponsor
James Bayley
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 1, 2026, 9:09 PM EDT
Completed No phase listed Observational

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

NCT02345356
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies, Pulmonary Embolism
Interventions
Genotype-guided, Standard-of-Care
Genetic · Other
Lead sponsor
University of Puerto Rico
Other
Eligibility
21 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Sep 1, 2026, 9:09 PM EDT
Not listed No phase listed Observational

The DARE Warfarin CER Study

NCT03271450
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
416,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 1, 2026, 9:09 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Upper Extremity Deep-Vein Thrombosis

NCT00245856
View directory record Official record
Conditions
Deep-Vein Thrombosis
Interventions
Dalteparin sodium injection, Warfarin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 1, 2026, 9:09 PM EDT